Alzecure Pharma Stock Current Valuation
| ALZCUR Stock | SEK 2.48 0.32 11.43% |
Valuation analysis of AlzeCure Pharma helps investors to measure AlzeCure Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that AlzeCure Pharma's price fluctuation is extremely dangerous at this time. Calculation of the real value of AlzeCure Pharma is based on 3 months time horizon. Increasing AlzeCure Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AlzeCure Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AlzeCure Stock. However, AlzeCure Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.48 | Real 1.96 | Hype 2.48 |
The real value of AlzeCure Stock, also known as its intrinsic value, is the underlying worth of AlzeCure Pharma Company, which is reflected in its stock price. It is based on AlzeCure Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AlzeCure Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AlzeCure Pharma helps investors to forecast how AlzeCure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AlzeCure Pharma more accurately as focusing exclusively on AlzeCure Pharma's fundamentals will not take into account other important factors: AlzeCure Pharma Company Current Valuation Analysis
AlzeCure Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AlzeCure Pharma Current Valuation | 173.51 M |
Most of AlzeCure Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AlzeCure Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AlzeCure Pharma has a Current Valuation of 173.51 M. This is 98.79% lower than that of the Healthcare sector and 97.67% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Sweden stocks is 98.96% higher than that of the company.
AlzeCure Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AlzeCure Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AlzeCure Pharma could also be used in its relative valuation, which is a method of valuing AlzeCure Pharma by comparing valuation metrics of similar companies.AlzeCure Pharma is currently under evaluation in current valuation category among its peers.
AlzeCure Fundamentals
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 173.51 M | |||
| Shares Outstanding | 59.19 M | |||
| Shares Owned By Insiders | 41.31 % | |||
| Shares Owned By Institutions | 6.48 % | |||
| Price To Book | 6.62 X | |||
| EBITDA | (77.2 M) | |||
| Net Income | (77.78 M) | |||
| Cash And Equivalents | 222.05 M | |||
| Cash Per Share | 5.88 X | |||
| Current Ratio | 48.05 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (70.64 M) | |||
| Earnings Per Share | (1.78) X | |||
| Target Price | 11.88 | |||
| Number Of Employees | 14 | |||
| Beta | 0.76 | |||
| Market Capitalization | 254.44 M | |||
| Total Asset | 45.65 M | |||
| Z Score | -3.3 | |||
| Net Asset | 45.65 M |
About AlzeCure Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AlzeCure Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AlzeCure Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AlzeCure Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in AlzeCure Stock
AlzeCure Pharma financial ratios help investors to determine whether AlzeCure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AlzeCure with respect to the benefits of owning AlzeCure Pharma security.